Targeting and anti-tumor efficacy of liposomal 5′-O-dipalmitoylphosphatidyl 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma

被引:6
作者
Asai, T
Shuto, S
Matsuda, A
Kakiuchi, T
Ohba, H
Tsukada, H
Oku, N
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Dept Radiobiochem, Shizuoka 4228526, Japan
[2] Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan
[3] Hamamatsu Photon KK, Shizuoka 4340041, Japan
基金
日本学术振兴会;
关键词
liposomes; drug delivery system; 2 '-C-cyano-2 '-deoxy-1-beta-D-arabino-pentofuranosylcytosine; 5 '-O-dipalmitoplphosphatidyl derivative of CNDAC; pulmonary cancer; positron emission tomography;
D O I
10.1016/S0304-3835(00)00633-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2'-C-cyano-2'-deoxy-1-beta -D-arabino-pentofuranosylcytosine (CNDAC) is a potent anti-cancer agent, and we previously observed that liposomal formulation of 5'-O-dipalmitoylphosphatidyl derivative of CNDAC (DPP-CNDAC) is desirable for targeting. For targeting to pulmonary cancer, we investigated the in vivo behavior of liposomes containing DPP-CNDAC by a non-invasive method using positron emission tomography. Liposomes composed of DPP-CNDAC and cholesterol (DPP-CNDAC/CH liposomes) were markedly accumulated in mice lung bearing B16BL6 melanoma. In metastatic pulmonary cancer model, DPP-CNDAC/CH liposomes significantly reduced the lung colonization in a dose-dependent manner. The activity was significantly superior to conventional liposomal formulation or soluble CNDAC. These results suggest that DPP-CNDAC/CH liposomes are useful for metastatic pulmonary cancer. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 25 条
[11]   NUCLEOSIDES AND NUCLEOTIDES .100. 2'-C-CYANO-2'-DEOXY-1-BETA-D-ARABINOFURANOSYLCYTOSINE (CNDAC) - DESIGN OF A POTENTIAL MECHANISM-BASED DNA-STRAND-BREAKING ANTINEOPLASTIC NUCLEOSIDE [J].
MATSUDA, A ;
NAKAJIMA, Y ;
AZUMA, A ;
TANAKA, M ;
SASAKI, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (09) :2917-2919
[12]  
MATSUDA A, 1990, NUCL ACIDS S, V22, P51
[13]   Development and biochemical characterization of a 2′-C-cyano-2′ deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080 [J].
Obata, T ;
Endo, Y ;
Tanaka, M ;
Matsuda, A ;
Sasaki, T .
CANCER LETTERS, 1998, 123 (01) :53-61
[14]  
Oku N, 1996, BIOPHARM DRUG DISPOS, V17, P435, DOI 10.1002/(SICI)1099-081X(199607)17:5<435::AID-BDD435>3.0.CO
[15]  
2-K
[16]   Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography [J].
Oku, N ;
Tokudome, Y ;
Namba, Y ;
Saito, N ;
Endo, M ;
Hasegawa, Y ;
Kawai, M ;
Tsukada, H ;
Okada, S .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1996, 1280 (01) :149-154
[17]   Delivery of contrast agents for positron emission tomography imaging by liposomes [J].
Oku, N .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 37 (1-3) :53-61
[18]   REAL-TIME ANALYSIS OF LIPOSOMAL TRAFFICKING IN TUMOR-BEARING MICE BY USE OF POSITRON EMISSION TOMOGRAPHY [J].
OKU, N ;
TOKUDOME, Y ;
TSUKADA, H ;
OKADA, S .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1995, 1238 (01) :86-90
[19]   Anticancer therapy using glucuronate modified long-circulating liposomes [J].
Oku, N .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 40 (1-2) :63-73
[20]   DEACYLATION REACYLATION CYCLE - A POSSIBLE ABSORPTION MECHANISM FOR THE NOVEL LYMPHOTROPIC ANTITUMOR AGENT DIPALMITOYLPHOSPHATIDYLFLUOROURIDINE IN RATS [J].
SAKAI, A ;
MORI, N ;
SHUTO, S ;
SUZUKI, T .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 82 (06) :575-578